Results 61 to 70 of about 2,233 (157)

Spanish translation: Tezepelumab for the treatment of severe asthma: a plain language summary of the PATHWAY and NAVIGATOR studies

What is this summary about? This is a summary of the results of 2 clinical studies that looked at a medicine called tezepelumab. Tezepelumab is approved in the United States of America (USA), the European Union (EU) and several other countries for the ...
Gun Almqvist (3626828), Christopher E Brightling (7668680), Johan Bimmel (18085726), Janet M Griffiths (17065597), Arnaud Bourdin (376853), Elliot Israel (153177), Andrew Menzies-Gow (603619), Karin Bowen (6991781), Michael E Wechsler (13266985), Jonathan Corren (9654556), Gene Colice (5129612), Anthony McGuinness (18085729), Sandhia Ponnarambil (14640482)   +12 more
core   +1 more source

German translation: Tezepelumab for the treatment of severe asthma: a plain language summary of the PATHWAY and NAVIGATOR studies

What is this summary about? This is a summary of the results of 2 clinical studies that looked at a medicine called tezepelumab. Tezepelumab is approved in the United States of America (USA), the European Union (EU) and several other countries for the ...
Gun Almqvist (3626828), Christopher E Brightling (7668680), Johan Bimmel (18085726), Janet M Griffiths (17065597), Arnaud Bourdin (376853), Elliot Israel (153177), Andrew Menzies-Gow (603619), Karin Bowen (6991781), Michael E Wechsler (13266985), Jonathan Corren (9654556), Gene Colice (5129612), Anthony McGuinness (18085729), Sandhia Ponnarambil (14640482)   +12 more
core   +1 more source

Tezepelumab: patient selection and place in therapy in severe asthma

Journal of International Medical Research
Asthma is a disease characterised by heterogeneous and multifaceted airway inflammation. Despite the availability of effective treatments, a substantial percentage of patients with the type 2 (T2)-high, but mainly the T2-low, phenotype complain of persistent symptoms, airflow limitation, and poor response to treatments.
Francesco Menzella, Sara Munari, Lorenzo Corsi, Silvia Tonin, Walter Cestaro, Andrea Ballarin, Ariel Floriani, Cristina Dartora, Gianenrico Senna   +8 more
openaire   +3 more sources

Japanese translation: Tezepelumab for the treatment of severe asthma: a plain language summary of the PATHWAY and NAVIGATOR studies

What is this summary about? This is a summary of the results of 2 clinical studies that looked at a medicine called tezepelumab. Tezepelumab is approved in the United States of America (USA), the European Union (EU) and several other countries for the ...
Gun Almqvist (3626828), Christopher E Brightling (7668680), Johan Bimmel (18085726), Janet M Griffiths (17065597), Arnaud Bourdin (376853), Elliot Israel (153177), Andrew Menzies-Gow (603619), Karin Bowen (6991781), Michael E Wechsler (13266985), Jonathan Corren (9654556), Gene Colice (5129612), Anthony McGuinness (18085729), Sandhia Ponnarambil (14640482)   +12 more
core   +1 more source

French translation: Tezepelumab for the treatment of severe asthma: a plain language summary of the PATHWAY and NAVIGATOR studies

What is this summary about? This is a summary of the results of 2 clinical studies that looked at a medicine called tezepelumab. Tezepelumab is approved in the United States of America (USA), the European Union (EU) and several other countries for the ...
Gun Almqvist (3626828), Christopher E Brightling (7668680), Johan Bimmel (18085726), Janet M Griffiths (17065597), Arnaud Bourdin (376853), Elliot Israel (153177), Andrew Menzies-Gow (603619), Karin Bowen (6991781), Michael E Wechsler (13266985), Jonathan Corren (9654556), Gene Colice (5129612), Anthony McGuinness (18085729), Sandhia Ponnarambil (14640482)   +12 more
core   +1 more source

Tezepelumab improved chronic eosinophilic pneumonia in severe asthma patients with liver cirrhosis [PDF]

Systemic administration of corticosteroids is used in the treatment of chronic eosinophilic pneumonia (CEP). However, in patients with CEP as well as other comorbidities, the adverse effects of corticosteroids should be minimized as much as possible.
Yusuke Nakamura, Mizuki Inaba, Yasuo Shimizu, Seiji Niho, Hiroaki Okutomi, Akihiro Takemasa   +5 more
core   +1 more source

Efficacy of tezepelumab in patients with severe asthma and persistent airflow obstruction

Background Persistent airflow obstruction (PAO) in patients with asthma can be difficult to treat. Tezepelumab blocks thymic stromal lymphopoietin, an epithelial cytokine implicated in asthma pathogenesis.
Neil Martin, Nestor A. Molfino, Elliot Israel, Sandhia S. Ponnarambil, Nicole L. Martin, Christopher S. Ambrose, Jean-Pierre Llanos, Mario Castro   +7 more
core   +1 more source

Efficacy and Safety of Tezepelumab in Adults With Severe, Uncontrolled Asthma in Asia: Results From the Phase 3 DIRECTION Study

BACKGROUND: Tezepelumab, a human monoclonal antibody that blocks thymic stromal lymphopoietin, reduced the annualized asthma exacerbation rate (AAER) and improved lung function, asthma control, and health-related quality of life (HRQoL) in patients with ...
Jiang, W, Ponnarambil, SS, Lal, H, Wu, CC, Yang, X, Domek-Zielinska, K, Tang, W, Park, HS, Wang, L, Min, CW, Berame, EJ, Molfino, NA, Zhong, N, Huang, K, Hunter, G   +14 more
core   +1 more source

Tezepelumab for refractory eosinophilic granulomatosis with polyangiitis-related asthma

International audienceAbstract Conventional immunosuppressants are ineffective for the management of EGPA-related asthma. Tezepelumab is a human monoclonal antibody that inhibits thymic stromal lymphopoietin (TLSP) that has proven efficacy in several ...
Tcherakian, Colas, Marquant, Quentin, Catherinot, Emilie, Vincent-Galtié, Nina, Ackermann, Felix, Magnan, Antoine, Groh, Matthieu   +6 more
core   +1 more source

Sequential Use of Tezepelumab and Bronchoscopic Lung Volume Reduction With Endobronchial Valves in a Patient With Severe Asthma‐COPD Overlap and Heterogeneous Emphysema: A Case Report

Asthma‐COPD overlap (ACO) carries greater symptom burden, frequent exacerbations and impaired quality of life compared with asthma or COPD alone. Evidence‐based advanced therapies are lacking, and management is typically extrapolated from existing ...
Jonas Herth, Daniel Franzen, Herth, Jonas; https://orcid.org/, Franzen, Daniel; https://orcid.org/   +3 more
core   +1 more source